Patients with new-onset type 1 diabetes had higher rates of beta-cell death compared with those who had long-standing diabetes and those without diabetes, a study found. However, teplizumab treatment was associated with lower beta-cell death and better beta-cell function in patients with new-onset diabetes, researchers wrote in the journal Diabetes.
Teplizumab curbs beta-cell death in new-onset type 1 diabetes
SmartBrief Job Listings for Health Care
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|
|Director Account Management||
Samaritan Health Services
|Hospital Medical Device Sales||
Linda Hertz Group